GPT and Hyperglycemia: As with most glycosaminoglycans, CaG and IQG brought about a reduction in serum levels of inflammation-related parameters: free fatty acid, AST (SGPT), creatinine kinase (related heart function), glucose, uric acid, and hyperglycemia related levels: cholesterol, total, triglyceride, LDL cholesterol, etc. The free fatty acid levels (related fatty liver) of the treated groups were statistically significantly decreased, 36.7% in the CaG group and 40.94% in the IQG group.